Every patient education resource tells you to ask questions before enrolling in a clinical trial. Few explain which questions actually change your understanding of what you're signing up for. The right questions surface information the consent form buries, glosses over, or leaves for you to infer. This guide walks through 7 categories of questions, what each category reveals, and why the answers matter.
Asking good questions is not aggressive or distrustful. It is the foundation of informed consent.
What the Study Drug Actually Does
Before you take any investigational drug, you need to understand its mechanism. This goes beyond reading the drug name and disease indication. The mechanism explains how researchers believe the drug works at the cellular or molecular level, and that mechanism determines which adverse events you're most likely to experience.
If a drug is designed to inhibit a specific protein, and that protein is also active in your liver, then liver toxicity becomes a plausible side effect even if it hasn't appeared yet in human testing. When researchers studied gene therapies for spinal muscular atrophy, understanding the mechanism helped predict that immune responses (not paralysis progression) would be the limiting factor.
Ask the research coordinator what the proposed mechanism of action is. What tissues or cell types is the drug expected to affect? What side effects have appeared in prior phase testing, even if they were rare? What adverse events is the team actively monitoring for?
Also ask whether earlier phases are fully published yet. If Phase 1b safety data exists but hasn't appeared in a peer-reviewed journal, ask for a summary. Pre-publication data is real data.
How the Trial's Structure Affects You
Trial design determines whether you might receive placebo, how long you stay in the study, and whether you get a chance to cross over to active drug if you're randomized to placebo. These structural details reshape your experience before the first injection or pill.
Randomization and Placebo
Is the trial randomized? If yes, what's the ratio? A 1-to-1 ratio means equal odds of drug or placebo. A 2-to-1 ratio means two-thirds of participants get drug, one-third get placebo. Some trials use 3-to-1 or 4-to-1 ratios, which improve your odds.
For progressive rare diseases, the placebo odds matter enormously. A patient with Hunter syndrome enrolled in a 1-to-1 randomized trial accepts a 50% chance of 6 months without any disease-modifying therapy, which could mean measurable cognitive or physical decline. That's different from a patient enrolling in an open-label trial where everyone receives the study drug.
Blinding and When You Find Out
Who knows whether you're on drug or placebo during the trial? In a blinded trial, neither you nor the research team know what you're receiving (though this is broken in emergencies). In an open-label trial, everyone knows. Some trials are partially blinded, where you don't know but the team does, or vice versa.
A blinded trial protects the scientific integrity of results. It also means you won't know for months whether you're experiencing the drug's effects or a placebo response. Some patients find uncertainty manageable. Others find it psychologically costly.
Crossover and Open-Label Extension
If you're randomized to placebo, is there a crossover point where you can receive active drug? Some trials design this in from the start. Others don't. If there's no crossover, ask whether an open-label extension will be available after the randomized phase, allowing patients on placebo to receive the drug.
The answer tells you whether enrollment in a placebo-controlled trial could leave you on placebo for the entire study duration with no access to the investigational drug afterward.
What Monitoring and Safety Checks Happen
Clinical trials collect enormous amounts of safety data. The frequency and type of monitoring determines how quickly researchers will catch adverse events if they occur, and how much of your time and health the trial consumes.
Visit Frequency and Duration
How many visits happen during treatment? How long is each visit? Is monitoring daily, weekly, monthly, or every few months? Some trials for rare diseases require weekly visits. Others require quarterly visits with monthly telehealth check-ins in between.
Ask specifically how much time you should expect at each visit. Do you need to fast beforehand? Will you be sedated for any procedures? Can any testing happen at a local lab, or must everything be done at the main trial site?
What Happens at Home Between Visits
Some trials require home monitoring. You might need to measure symptoms daily, take blood pressure readings, wear a heart monitor, or report side effects in a patient diary. Ask whether the trial expects you to track your condition between visits, and how you'll report problems.
More importantly, ask what happens if you experience a serious adverse event at home on a Friday evening when the clinic is closed. Is there a 24/7 hotline? Do you call 911? Should you go to an emergency room near home, or drive to the trial site?
How This Fits Into Your Daily Life
Trial logistics determine whether you can work, care for dependents, manage other health needs, or sustain your normal routine during the study period.
Where is the trial site relative to your home? Rare disease trials have few sites. If the site is distant, ask whether any visits can happen at a satellite clinic closer to home, or whether the trial allows a local physician to supervise some tests with results sent to the primary site. Ask whether the trial covers travel expenses. Some do. Most don't.
Does the trial schedule allow you to continue working? Some trials have evening or weekend appointment slots. Others don't. If appointments are standard business hours, taking time off work every week becomes a cost. If you need a caregiver to drive you, attend appointments, or monitor your condition, ask whether the trial accommodates that.
What other medications will you need to avoid or pause? What activities are restricted? A trial that requires you to stop your antihypertensive medication, restrict salt, avoid NSAIDs, and refrain from exercise is manageable in some seasons of life and not in others.
What Your Options Are if You Want to Leave
Trial enrollment is voluntary. You can withdraw at any time. The protocol should explain what happens when you do, but many patients never ask.
If you decide to withdraw, can you stop taking the drug immediately, or is there a tapering protocol? Some drugs require gradual dose reduction to avoid rebound effects. Others can be stopped abruptly. Ask also whether you need to stay for a final safety visit after withdrawal, or whether you can stop and leave immediately. Most protocols require at least one final visit.
If you withdraw because the drug is working and you want to keep taking it, can you enroll in an open-label extension? If you withdraw because of unacceptable side effects, can you restart your prior treatment immediately, or will your physician need to taper you back onto it carefully?
The trial team might also withdraw you if you become ineligible. Your disease might progress beyond the inclusion criteria. You might develop a new condition that disqualifies you. Ask what triggers mandatory withdrawal and what your access to the drug or follow-up care looks like if the trial stops you.
What Happens if the Drug Works
This is the question most patients hesitate to ask, as if asking means tempting fate. Ask anyway. If the study drug shows benefit, your access to it after the trial should not depend on factors the trial team chose not to plan for.
Is an open-label extension planned in the protocol? If the drug works in Phase 2b or Phase 3, will all participants have the option to continue receiving it? Some sponsors commit to this upfront. Others decide later based on regulatory feedback.
If no open-label extension exists, has the sponsor committed to expanded access under FDA regulations? Expanded access is different from commercial availability. It allows patients to access a drug that hasn't been approved yet, in limited cases. Rare disease sponsors are more likely to offer this than sponsors working on common diseases.
What's the realistic timeline to FDA approval? Is the drug 1 year away or 5? If it's approved, will your insurance cover it? Novel therapies for rare diseases often cost tens of thousands of dollars annually. These aren't questions the trial coordinator enjoys answering, yet they determine whether you can actually access the drug that helped you.
What Nobody Asks (and Everyone Should)
Clinical trial dropout rates carry enormous information. If 40% of participants drop out in earlier phases, that tells you something is wrong with tolerability, logistics, or efficacy. Dropout data is a red flag sensor.
Ask the research coordinator what the dropout rate was in earlier phases of this program. Ask how many participants have already enrolled at this site and others. If enrollment is stalling late in the trial, it often means recruitment is harder than anticipated, or word of mouth about side effects has spread.
Also ask about compensability. If the study drug causes an injury, who pays for your medical treatment? The trial sponsor typically carries insurance for trial-related injuries, but the coverage is limited. Ask directly whether the protocol covers trial-related injuries, what the coverage limits are, and what recourse you have.
High dropout is not automatically disqualifying. It might mean the prior phase population was sicker than the current phase, or younger participants dropped out while older ones persisted. It deserves explanation, not silence.
This Is Part of a Series
This post is the third in our 4-part series on clinical trial participation. If you haven't read the earlier posts, start with how to evaluate whether a clinical trial is right for you and then how to talk to your doctor about clinical trials.
Once you've asked your questions and decided to move forward, our final post covers what happens after you express interest in a clinical trial. You can also read the full series overview.